Karmijn specialises in competition law and one of her areas of expertise is healthcare mergers, particularly by private equity, and related matters. Karmijn litigates in both administrative law and civil law (cartel damages) cases. She liaises frequently with the Netherlands Authority for Consumers and Markets (ACM) and the European Commission.

In addition to her legal practice, Karmijn takes on the role of mentor for the Willem C. Vis Moot Court Team at the University of Amsterdam, guiding the next generation of legal minds

  • Advised Angelo Gordon on the acquisition of shares and membership rights in 26 entities, resulting in the acquisition of a real estate portfolio consisting of 86 buildings with 2,946 residential units and commercial spaces by a group of investors led by TPG Angelo Gordon for an amount of approximately EUR 700 million.
  • Advised Castik Capital S.a.r.l. on the acquisition of paraDIGMA Group.
  • Represented one of the major airlines involved in the air cargo cartel Dutch civil damage proceedings.
  • LL.M. EU Competition Law (University of Amsterdam)
  • LL.B. International & European Law (University of Groningen)

Expertises

Competition
We advise and assist national and international companies, institutions and governments in procedures before the Netherlands Authority for Consumers and Markets, the European Commission, foreign competition authorities, and the relevant (specialised) courts.
Healthcare
The healthcare sector is under pressure. Due to an ageing population and smarter but more expensive treatment methods, costs are increasing, while further rises in healthcare spending are frowned upon. That is why the government has introduced regulated market forces.
Competition
We advise and assist national and international companies, institutions and governments in procedures before the Netherlands Authority for Consumers and Markets, the European Commission, foreign competition authorities, and the relevant (specialised) courts.
Healthcare
The healthcare sector is under pressure. Due to an ageing population and smarter but more expensive treatment methods, costs are increasing, while further rises in healthcare spending are frowned upon. That is why the government has introduced regulated market forces.
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.